CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today results of a prospective analysis of the images from the Zemiva Phase 2b clinical trial using the company’s recently validated Normals reference database. Zemiva (iodofiltic acid I 123 or BMIPP) is being studied in the emergency department setting to rapidly detect acute coronary syndrome (ACS) and evaluate cardiac ischemia, which is caused by insufficient blood flow to the heart. Data presented demonstrated that Zemiva compares favorably to published performance parameters of approved cardiac blood flow tracers used to detect cardiac ischemia and myocardial infarction, or heart attack, but which are unable to provide timely and critically important information when a chest pain patient presents to the emergency department. Clinical trial results to date suggest that Zemiva can be used immediately upon patient presentation, at rest, and can provide crucial diagnostic information on presenting chest pain that may have occurred within the previous 30 hours. The data were reported in an oral presentation at the annual meeting of the American Society of Nuclear Cardiology (ASNC) in San Diego, California, by the study’s lead investigator, James Udelson, M.D., Associate Chief, Division of Cardiology and Director of Nuclear Cardiology at Tufts-New England Medical Center.
